S100A9 and myeloproliferative disorder: There was no significant difference between JAK2 and CALR mutant patients (Figure 5(b)), we also compared S100A9 levels in MPN patients with JAK2 (+) versus Jak2 (−), and fined no difference between the two groups, while MPN as a whole was significantly higher than controls (data not shown).